Drug Profile
Research programme: therapeutic peptides and antibodies - Amgen/Dyax
Latest Information Update: 09 Sep 2008
Price :
$50
*
At a glance
- Originator Amgen; Dyax
- Class Antibodies; Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 09 Sep 2008 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 14 Jun 2007 This programme is still in active development
- 24 Aug 2004 Preclinical trials in Undefined in USA (unspecified route)